CAR T-cell treatment for EGFR-mutant glioblastoma
Part of Cancer clinical trials.
This Phase 1 trial tests a new immune treatment made from your own immune cells to attack glioblastoma (a brain tumor), especially tumors with a specific EGFR change called EGFRvIII. It mainly focuses on safety and early signs of effectiveness, and some participants will also need surgery/biopsy and an implanted port for the treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older
- You have glioblastoma that is recurrent or newly diagnosed depending on the arm, and your tumor must match the study’s EGFR test (EGFRvIII yes or no)
- You must be able to have an MRI with contrast and have a measurable tumor spot on MRI (at least one lesion about 1 cm or bigger) for the study drug period
- Your general health and blood counts must be strong enough, including enough white blood cells and platelets, good kidney function, and acceptable liver test results
- You must be well enough to get the treatment setup (including having an Ommaya reservoir placed, and using steroids only up to the allowed dose)
- You must not have had certain prior treatments (like EGFRvIII-targeted therapy, gene-therapy/cell therapy, or bevacizumab) and you must avoid pregnancy
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial studies a personalized immune-cell treatment (CAR-T) for glioblastoma that has come back. It aims to shrink or control the regrowing brain tumor by using your own immune cells after processing them in a lab.
This trial tests a special immune cell treatment (CAR-T cells) that targets two proteins found on glioblastoma cells. It is for patients whose tumor has come back or not responded to standard treatments.
This trial tests a new treatment using engineered immune cells (CAR-NK cells) that target two markers found on glioblastoma tumors. The treatment is given directly into the brain to fight tumors that have come back after standard therapy.
This trial tests engineered immune cells (called NK cells) that are designed to fight glioblastoma, a deadly brain cancer. The cells are injected directly into the tumor and may help patients whose cancer has come back after standard treatment.
This trial tests a new treatment for recurrent glioblastoma, a type of brain cancer that has returned. The treatment uses your own immune cells, modified in a lab to find and attack a specific marker on the tumor, called EGFRvIII. It might help because it targets the cancer cells directly and may slow or stop their growth.
This trial tests a new type of immunotherapy called CAR T-cells that target a protein called GARP on your tumor cells. It is for people whose high-grade glioma (a fast-growing brain tumor) has come back after previous treatment.
Hear when a new Glioblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.